Neutralization of staphylococcal exotoxins in vitro by human-origin intravenous immunoglobulin

Abstract Human-origin intravenous immunoglobulin (IVIG) collected from healthy individuals was tested for its neutralizing activity against the hemolysin, toxic shock syndrome toxin-1 (TSST-1), and enterotoxins, produced by laboratory strains of methicillin-resistant Staphylococcus aureus (MRSA). Th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2007-12, Vol.13 (6), p.368-372
Hauptverfasser: Yanagisawa, Chie, Hanaki, Hideaki, Natae, Taiji, Sunakawa, Keisuke
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 372
container_issue 6
container_start_page 368
container_title Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
container_volume 13
creator Yanagisawa, Chie
Hanaki, Hideaki
Natae, Taiji
Sunakawa, Keisuke
description Abstract Human-origin intravenous immunoglobulin (IVIG) collected from healthy individuals was tested for its neutralizing activity against the hemolysin, toxic shock syndrome toxin-1 (TSST-1), and enterotoxins, produced by laboratory strains of methicillin-resistant Staphylococcus aureus (MRSA). The hemolytic activity of the culture supernatant against sheep red blood cells was reduced from 100% to 5.5% relative hemolysis in the presence of 0.156 mg protein/ml of IVIG. The maximum dilution endpoint of the culture supernatant for TSST-1-mediated latex aggregation was 32-fold. This level of TSST-1 activity was reduced to eightfold dilution by 0.78 mg protein/ml of IVIG, and the latex aggregation activity of undiluted TSST-1 in the culture supernatant was inhibited by 1.56 mg protein/ml of IVIG. Similarly, the enterotoxin A-mediated latex aggregation titer appeared to be a 320-fold dilution. This toxin activity was reduced to an 80-fold dilution and below a tenfold dilution by 0.049 through 0.78 and 1.56 mg protein/ml, respectively, of IVIG. These results show that IVIG has powerful neutralizing activity against hemolysin, TSST-1, and enterotoxin A. Therefore, IVIG may be useful for passive immunization therapy in patients suffering from diseases caused by MRSA exotoxins.
doi_str_mv 10.1007/s10156-007-0551-6
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20843559</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1341321X07708127</els_id><sourcerecordid>20843559</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-1b39291ffbe8c941136aa16bdd2cb132460292343f17e64b3fa662c2548ce6503</originalsourceid><addsrcrecordid>eNpFkT9PwzAQxT2AaCl8ABaUiS3gs2MnWZBQxT-pggGQmLAc12ldErvYSdXy6XHUSkx3Or17uvc7hC4AXwPG-U0ADIynsU0xY5DyIzQGmkFKCXyO0GkIK4whZ0VxgkZQ4JLhIhujrxfdd1425ld2xtnE1Uno5Hq5a5xySskm0VvXua2xITE22ZjOu6TaJcu-lTZ13izi1NhosdHW9VHUtr11i8ZVfWPsGTquZRP0-aFO0MfD_fv0KZ29Pj5P72apyqDsUqhoSUqo60oXqswAKJcSeDWfE1UBJRnHpCQ0ozXkmmcVrSXnRBGWFUpzhukEXe1919799Dp0ojVB6aaRVserBIlhKWNlFMJeqLwLwetarL1ppd8JwGIAKfYgxdAOIAWPO5cH875q9fx_40AxCm73Ah0jboz2QsXsJtL71jsdVq73NqYXIAIRWLwNfxnegvMcF0By-gdkiIdB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20843559</pqid></control><display><type>article</type><title>Neutralization of staphylococcal exotoxins in vitro by human-origin intravenous immunoglobulin</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Alma/SFX Local Collection</source><creator>Yanagisawa, Chie ; Hanaki, Hideaki ; Natae, Taiji ; Sunakawa, Keisuke</creator><creatorcontrib>Yanagisawa, Chie ; Hanaki, Hideaki ; Natae, Taiji ; Sunakawa, Keisuke</creatorcontrib><description>Abstract Human-origin intravenous immunoglobulin (IVIG) collected from healthy individuals was tested for its neutralizing activity against the hemolysin, toxic shock syndrome toxin-1 (TSST-1), and enterotoxins, produced by laboratory strains of methicillin-resistant Staphylococcus aureus (MRSA). The hemolytic activity of the culture supernatant against sheep red blood cells was reduced from 100% to 5.5% relative hemolysis in the presence of 0.156 mg protein/ml of IVIG. The maximum dilution endpoint of the culture supernatant for TSST-1-mediated latex aggregation was 32-fold. This level of TSST-1 activity was reduced to eightfold dilution by 0.78 mg protein/ml of IVIG, and the latex aggregation activity of undiluted TSST-1 in the culture supernatant was inhibited by 1.56 mg protein/ml of IVIG. Similarly, the enterotoxin A-mediated latex aggregation titer appeared to be a 320-fold dilution. This toxin activity was reduced to an 80-fold dilution and below a tenfold dilution by 0.049 through 0.78 and 1.56 mg protein/ml, respectively, of IVIG. These results show that IVIG has powerful neutralizing activity against hemolysin, TSST-1, and enterotoxin A. Therefore, IVIG may be useful for passive immunization therapy in patients suffering from diseases caused by MRSA exotoxins.</description><identifier>ISSN: 1341-321X</identifier><identifier>DOI: 10.1007/s10156-007-0551-6</identifier><identifier>PMID: 18095084</identifier><language>eng</language><publisher>Netherlands</publisher><subject>Bacterial Toxins - genetics ; Bacterial Toxins - immunology ; Enterotoxins - genetics ; Enterotoxins - immunology ; Exotoxins - immunology ; Hematology, Oncology and Palliative Medicine ; Hemolysin Proteins - genetics ; Hemolysin Proteins - immunology ; Humans ; Immunoglobulins, Intravenous - immunology ; Latex Fixation Tests ; Methicillin Resistance ; Staphylococcal Infections - immunology ; Staphylococcus aureus ; Staphylococcus aureus - drug effects ; Staphylococcus aureus - genetics ; Staphylococcus aureus - immunology ; Superantigens - genetics ; Superantigens - immunology</subject><ispartof>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2007-12, Vol.13 (6), p.368-372</ispartof><rights>Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-1b39291ffbe8c941136aa16bdd2cb132460292343f17e64b3fa662c2548ce6503</citedby><cites>FETCH-LOGICAL-c419t-1b39291ffbe8c941136aa16bdd2cb132460292343f17e64b3fa662c2548ce6503</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18095084$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yanagisawa, Chie</creatorcontrib><creatorcontrib>Hanaki, Hideaki</creatorcontrib><creatorcontrib>Natae, Taiji</creatorcontrib><creatorcontrib>Sunakawa, Keisuke</creatorcontrib><title>Neutralization of staphylococcal exotoxins in vitro by human-origin intravenous immunoglobulin</title><title>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</title><addtitle>J Infect Chemother</addtitle><description>Abstract Human-origin intravenous immunoglobulin (IVIG) collected from healthy individuals was tested for its neutralizing activity against the hemolysin, toxic shock syndrome toxin-1 (TSST-1), and enterotoxins, produced by laboratory strains of methicillin-resistant Staphylococcus aureus (MRSA). The hemolytic activity of the culture supernatant against sheep red blood cells was reduced from 100% to 5.5% relative hemolysis in the presence of 0.156 mg protein/ml of IVIG. The maximum dilution endpoint of the culture supernatant for TSST-1-mediated latex aggregation was 32-fold. This level of TSST-1 activity was reduced to eightfold dilution by 0.78 mg protein/ml of IVIG, and the latex aggregation activity of undiluted TSST-1 in the culture supernatant was inhibited by 1.56 mg protein/ml of IVIG. Similarly, the enterotoxin A-mediated latex aggregation titer appeared to be a 320-fold dilution. This toxin activity was reduced to an 80-fold dilution and below a tenfold dilution by 0.049 through 0.78 and 1.56 mg protein/ml, respectively, of IVIG. These results show that IVIG has powerful neutralizing activity against hemolysin, TSST-1, and enterotoxin A. Therefore, IVIG may be useful for passive immunization therapy in patients suffering from diseases caused by MRSA exotoxins.</description><subject>Bacterial Toxins - genetics</subject><subject>Bacterial Toxins - immunology</subject><subject>Enterotoxins - genetics</subject><subject>Enterotoxins - immunology</subject><subject>Exotoxins - immunology</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Hemolysin Proteins - genetics</subject><subject>Hemolysin Proteins - immunology</subject><subject>Humans</subject><subject>Immunoglobulins, Intravenous - immunology</subject><subject>Latex Fixation Tests</subject><subject>Methicillin Resistance</subject><subject>Staphylococcal Infections - immunology</subject><subject>Staphylococcus aureus</subject><subject>Staphylococcus aureus - drug effects</subject><subject>Staphylococcus aureus - genetics</subject><subject>Staphylococcus aureus - immunology</subject><subject>Superantigens - genetics</subject><subject>Superantigens - immunology</subject><issn>1341-321X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkT9PwzAQxT2AaCl8ABaUiS3gs2MnWZBQxT-pggGQmLAc12ldErvYSdXy6XHUSkx3Or17uvc7hC4AXwPG-U0ADIynsU0xY5DyIzQGmkFKCXyO0GkIK4whZ0VxgkZQ4JLhIhujrxfdd1425ld2xtnE1Uno5Hq5a5xySskm0VvXua2xITE22ZjOu6TaJcu-lTZ13izi1NhosdHW9VHUtr11i8ZVfWPsGTquZRP0-aFO0MfD_fv0KZ29Pj5P72apyqDsUqhoSUqo60oXqswAKJcSeDWfE1UBJRnHpCQ0ozXkmmcVrSXnRBGWFUpzhukEXe1919799Dp0ojVB6aaRVserBIlhKWNlFMJeqLwLwetarL1ppd8JwGIAKfYgxdAOIAWPO5cH875q9fx_40AxCm73Ah0jboz2QsXsJtL71jsdVq73NqYXIAIRWLwNfxnegvMcF0By-gdkiIdB</recordid><startdate>200712</startdate><enddate>200712</enddate><creator>Yanagisawa, Chie</creator><creator>Hanaki, Hideaki</creator><creator>Natae, Taiji</creator><creator>Sunakawa, Keisuke</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope></search><sort><creationdate>200712</creationdate><title>Neutralization of staphylococcal exotoxins in vitro by human-origin intravenous immunoglobulin</title><author>Yanagisawa, Chie ; Hanaki, Hideaki ; Natae, Taiji ; Sunakawa, Keisuke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-1b39291ffbe8c941136aa16bdd2cb132460292343f17e64b3fa662c2548ce6503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Bacterial Toxins - genetics</topic><topic>Bacterial Toxins - immunology</topic><topic>Enterotoxins - genetics</topic><topic>Enterotoxins - immunology</topic><topic>Exotoxins - immunology</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Hemolysin Proteins - genetics</topic><topic>Hemolysin Proteins - immunology</topic><topic>Humans</topic><topic>Immunoglobulins, Intravenous - immunology</topic><topic>Latex Fixation Tests</topic><topic>Methicillin Resistance</topic><topic>Staphylococcal Infections - immunology</topic><topic>Staphylococcus aureus</topic><topic>Staphylococcus aureus - drug effects</topic><topic>Staphylococcus aureus - genetics</topic><topic>Staphylococcus aureus - immunology</topic><topic>Superantigens - genetics</topic><topic>Superantigens - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yanagisawa, Chie</creatorcontrib><creatorcontrib>Hanaki, Hideaki</creatorcontrib><creatorcontrib>Natae, Taiji</creatorcontrib><creatorcontrib>Sunakawa, Keisuke</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yanagisawa, Chie</au><au>Hanaki, Hideaki</au><au>Natae, Taiji</au><au>Sunakawa, Keisuke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neutralization of staphylococcal exotoxins in vitro by human-origin intravenous immunoglobulin</atitle><jtitle>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</jtitle><addtitle>J Infect Chemother</addtitle><date>2007-12</date><risdate>2007</risdate><volume>13</volume><issue>6</issue><spage>368</spage><epage>372</epage><pages>368-372</pages><issn>1341-321X</issn><abstract>Abstract Human-origin intravenous immunoglobulin (IVIG) collected from healthy individuals was tested for its neutralizing activity against the hemolysin, toxic shock syndrome toxin-1 (TSST-1), and enterotoxins, produced by laboratory strains of methicillin-resistant Staphylococcus aureus (MRSA). The hemolytic activity of the culture supernatant against sheep red blood cells was reduced from 100% to 5.5% relative hemolysis in the presence of 0.156 mg protein/ml of IVIG. The maximum dilution endpoint of the culture supernatant for TSST-1-mediated latex aggregation was 32-fold. This level of TSST-1 activity was reduced to eightfold dilution by 0.78 mg protein/ml of IVIG, and the latex aggregation activity of undiluted TSST-1 in the culture supernatant was inhibited by 1.56 mg protein/ml of IVIG. Similarly, the enterotoxin A-mediated latex aggregation titer appeared to be a 320-fold dilution. This toxin activity was reduced to an 80-fold dilution and below a tenfold dilution by 0.049 through 0.78 and 1.56 mg protein/ml, respectively, of IVIG. These results show that IVIG has powerful neutralizing activity against hemolysin, TSST-1, and enterotoxin A. Therefore, IVIG may be useful for passive immunization therapy in patients suffering from diseases caused by MRSA exotoxins.</abstract><cop>Netherlands</cop><pmid>18095084</pmid><doi>10.1007/s10156-007-0551-6</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1341-321X
ispartof Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2007-12, Vol.13 (6), p.368-372
issn 1341-321X
language eng
recordid cdi_proquest_miscellaneous_20843559
source MEDLINE; Springer Nature - Complete Springer Journals; Alma/SFX Local Collection
subjects Bacterial Toxins - genetics
Bacterial Toxins - immunology
Enterotoxins - genetics
Enterotoxins - immunology
Exotoxins - immunology
Hematology, Oncology and Palliative Medicine
Hemolysin Proteins - genetics
Hemolysin Proteins - immunology
Humans
Immunoglobulins, Intravenous - immunology
Latex Fixation Tests
Methicillin Resistance
Staphylococcal Infections - immunology
Staphylococcus aureus
Staphylococcus aureus - drug effects
Staphylococcus aureus - genetics
Staphylococcus aureus - immunology
Superantigens - genetics
Superantigens - immunology
title Neutralization of staphylococcal exotoxins in vitro by human-origin intravenous immunoglobulin
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T14%3A31%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neutralization%20of%20staphylococcal%20exotoxins%20in%20vitro%20by%20human-origin%20intravenous%20immunoglobulin&rft.jtitle=Journal%20of%20infection%20and%20chemotherapy%20:%20official%20journal%20of%20the%20Japan%20Society%20of%20Chemotherapy&rft.au=Yanagisawa,%20Chie&rft.date=2007-12&rft.volume=13&rft.issue=6&rft.spage=368&rft.epage=372&rft.pages=368-372&rft.issn=1341-321X&rft_id=info:doi/10.1007/s10156-007-0551-6&rft_dat=%3Cproquest_cross%3E20843559%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20843559&rft_id=info:pmid/18095084&rft_els_id=1_s2_0_S1341321X07708127&rfr_iscdi=true